Cellectis (CLLS) Equity Average (2015 - 2026)

Cellectis' Equity Average history runs 12 years deep, the most recent figure standing at $67.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 45.06% year-over-year to $67.9 million; the TTM figure through Mar 2026 stood at $67.9 million (down 45.06% YoY), while the FY2025 annual figure was $103.5 million, down 4.08% from the prior year.
• Equity Average was $67.9 million for Q1 2026 at Cellectis, down from $88.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $219.8 million in Q1 2022 to a low of $67.9 million in Q1 2026.
• Historically, Equity Average has averaged $121.8 million across 5 years, with a median of $119.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average tumbled 47.05% in 2023, then soared 61.96% in 2024.
• A 5-year view of Equity Average shows it stood at $135.8 million in 2022, then tumbled by 40.78% to $80.4 million in 2023, then jumped by 61.96% to $130.2 million in 2024, then slumped by 32.28% to $88.2 million in 2025, then slipped by 22.99% to $67.9 million in 2026.
• The last three Equity Average figures came in at $67.9 million (Q1 2026), $88.2 million (Q4 2025), and $98.8 million (Q3 2025), per Business Quant data.